Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation
about
Early diagnosis of pancreatic cancer: challenges and new developmentsTherapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.The Marker State Space (MSS) method for classifying clinical samples.Production of a recombinant antibody specific for i blood group antigen, a mesenchymal stem cell markerGlycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9.Glycoprotein disease markers and single protein-omicsGemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaGlycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis.Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins.Genetic correction improves prediction efficiency of serum tumor biomarkers on digestive cancer risk in the elderly Chinese cohort study.A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer.Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.
P2860
Q27014027-51BD6F24-C793-49F2-BFAC-52DED51C6C6CQ34585908-2FFD01F5-3590-43C8-A78C-5D495F14E1D1Q34764369-5B3B3524-5160-4EF0-B854-833C18005F4AQ35003304-0B4A23BA-C1A8-4A68-9F91-9F0045C150DAQ35583350-BD4E1FDB-5E23-4605-AA4A-D617ACCF9AD7Q35794259-BB27BAF8-20E6-417C-B195-EDC17D698CA5Q35797487-4D34010C-83F1-4239-BE00-FE42DE7CABB0Q36687536-63BF222F-601A-4FD1-90D6-AD28923FAC1BQ36742398-66F45611-C4AE-4D7D-9521-FA120EEE2B54Q36822841-0D57264E-DA3B-4E81-8A60-1A9EDF1B5D2AQ37714287-875FCEE5-D06A-4254-BD36-9F07A88BF4CDQ40980684-ACEB274A-0B2E-402D-9B5D-00859A901204Q50329875-2B14A3AF-8047-4868-A7BA-9C95013625AFQ50888469-EE09D561-3C5E-48C5-BE67-20D1B449109BQ52595056-68A30E51-2CEA-4462-AB94-1FA542E8DBCF
P2860
Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diverse monoclonal antibodies ...... es for clinical interpretation
@en
Diverse monoclonal antibodies ...... s for clinical interpretation.
@nl
type
label
Diverse monoclonal antibodies ...... es for clinical interpretation
@en
Diverse monoclonal antibodies ...... s for clinical interpretation.
@nl
prefLabel
Diverse monoclonal antibodies ...... es for clinical interpretation
@en
Diverse monoclonal antibodies ...... s for clinical interpretation.
@nl
P2093
P2860
P356
P1433
P1476
Diverse monoclonal antibodies ...... es for clinical interpretation
@en
P2093
Brian B Haab
Katie Partyka
Kevin A Maupin
Randall E Brand
P2860
P304
P356
10.1002/PMIC.201100676
P577
2012-07-01T00:00:00Z